179 related articles for article (PubMed ID: 23867634)
1. Successful everolimus treatment in a patient with advanced pancreatic neuroendocrine tumor who developed everolimus-induced interstitial lung disease on two occasions: a case report.
Nakayama Y; Ikeda M; Kojima M; Goto K; Hara M; Okuyama H; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Okusaka T
Chemotherapy; 2013; 59(1):74-8. PubMed ID: 23867634
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
[TBL] [Abstract][Full Text] [Related]
3. Role of everolimus in pancreatic neuroendocrine tumors.
Goldstein R; Meyer T
Expert Rev Anticancer Ther; 2011 Nov; 11(11):1653-65. PubMed ID: 21932937
[TBL] [Abstract][Full Text] [Related]
4. Patterns of interstitial lung disease during everolimus treatment in patients with metastatic renal cell carcinoma.
Mizuno R; Asano K; Mikami S; Nagata H; Kaneko G; Oya M
Jpn J Clin Oncol; 2012 May; 42(5):442-6. PubMed ID: 22438405
[TBL] [Abstract][Full Text] [Related]
5. Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.
Thompson LA; Kim M; Wenger SD; O'Bryant CL
Ann Pharmacother; 2012 Sep; 46(9):1212-9. PubMed ID: 22947595
[TBL] [Abstract][Full Text] [Related]
6. Everolimus dramatically improves glycemic control in unresectable metastatic insulinoma: a case report.
Asayama M; Yamada-Murano T; Hara H; Ooki A; Kurosumi M; Yamaguchi K
Jpn J Clin Oncol; 2014 Feb; 44(2):186-90. PubMed ID: 24367043
[TBL] [Abstract][Full Text] [Related]
7. Amenorrhea as a rare drug-related adverse event associated with everolimus for pancreatic neuroendocrine tumors.
Kawaguchi Y; Maruno A; Kawashima Y; Ito H; Ogawa M; Mine T
World J Gastroenterol; 2014 Nov; 20(42):15920-4. PubMed ID: 25400479
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effect of everolimus in a patient with type 3 gastric neuroendocrine tumor.
Bariani GM; Carvalheira JB; Riechelmann RP
Onkologie; 2013; 36(9):502-4. PubMed ID: 24051927
[TBL] [Abstract][Full Text] [Related]
9. Everolimus for the treatment of pancreatic neuroendocrine tumors.
Feldmann G; Bisht S; Schütte U; Haarmann J; Brossart P
Expert Opin Pharmacother; 2012 Oct; 13(14):2073-84. PubMed ID: 22873789
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological Characteristics of Everolimus-Associated Interstitial Lung Disease: A Single-Center Consecutive Analysis.
Saito Y; Terasaki Y; Kashiwada T; Tanaka T; Takei H; Kimura G; Kondo Y; Kawagoe T; Matsushita A; Noro R; Minegishi Y; Kamio K; Seike M; Gemma A
J Nippon Med Sch; 2024 May; 91(2):207-217. PubMed ID: 38233124
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas.
Bollard J; Couderc C; Blanc M; Poncet G; Lepinasse F; Hervieu V; Gouysse G; Ferraro-Peyret C; Benslama N; Walter T; Scoazec JY; Roche C
Neuroendocrinology; 2013; 97(4):331-40. PubMed ID: 23343749
[TBL] [Abstract][Full Text] [Related]
12. [Rechallenge of everolimus for metastatic renal cell carcinoma after recovery from grade 3 interstitial lung disease: a case report].
Utsunomiya N; Kono Y; Matsumoto K; Matsumoto T; Nakagawa A; Tsunemori H; Okada T; Muguruma K; Kawakita M
Hinyokika Kiyo; 2014 Jan; 60(1):25-8. PubMed ID: 24594769
[TBL] [Abstract][Full Text] [Related]
13. Long-term everolimus treatment of patients with pancreatic neuroendocrine tumors.
Wolin EM
Chemotherapy; 2014; 60(3):143-50. PubMed ID: 25766415
[TBL] [Abstract][Full Text] [Related]
14. Sequencing and combining systemic therapies for pancreatic neuroendocrine tumors.
Kulke MH
J Clin Oncol; 2015 May; 33(14):1534-8. PubMed ID: 25870092
[No Abstract] [Full Text] [Related]
15. Granuloma-forming interstitial pneumonia occurring one year after the start of everolimus therapy.
Saito Y; Kunugi S; Suzuki Y; Narita K; Miura Y; Minegishi Y; Kimura G; Kondo Y; Azuma A; Fukuda Y; Gemma A
Intern Med; 2013; 52(2):263-7. PubMed ID: 23318860
[TBL] [Abstract][Full Text] [Related]
16. Advances in pancreatic neuroendocrine tumor treatment.
van der Veldt AA; Kleijn SA
N Engl J Med; 2011 May; 364(19):1873; author reply 1873-5. PubMed ID: 21561355
[No Abstract] [Full Text] [Related]
17. Targeted agents in treatment of neuroendocrine tumors of pancreas.
Karampelas IN; Syrigos KN; Saif MW
JOP; 2014 Jul; 15(4):351-3. PubMed ID: 25076341
[TBL] [Abstract][Full Text] [Related]
18. Early Response to Everolimus Therapy Detected on 68Ga-DOTATATE PET/CT in a Patient With Pancreatic Neuroendocrine Tumor.
Ozkan E; Soydal C; Ucak Semirgin S; Yapici O; Atmaca A; Demirag G
Clin Nucl Med; 2016 Jul; 41(7):561-3. PubMed ID: 27163457
[TBL] [Abstract][Full Text] [Related]
19. Advances in the treatment of gastroenteropancreatic neuroendocrine tumors.
Phan AT
Clin Adv Hematol Oncol; 2014 Dec; 12(12 Suppl 19):3-5. PubMed ID: 25768101
[No Abstract] [Full Text] [Related]
20. Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.
Peng L; Schwarz RE
Curr Mol Med; 2013 Mar; 13(3):333-9. PubMed ID: 23331005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
